C12N2500/24

SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL
20230235282 · 2023-07-27 ·

Provided is a human-derived sensory neuron induction culture system. A combination of a small molecule inhibitor LY2157299 and a growth factor is added into a serum-free basal medium. Compared with an induction method involving serum, not only is the efficiency of inducing pluripotent stem cells into sensory neurons greatly improved, but the expression of a variety of ion channel proteins is also significantly improved, thereby achieving successful induction of multiple induced pluripotent stem cells from different sources into sensory neurons.

T-CELL MASTER CELL BANK

The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.

DIFFERENTIATION METHOD FOR PROCURING LARGE AMOUNT OF OLIGODENDROCYTES BY DISASSEMBLING 3D ORGANOIDS GENERATED FROM HUMAN PLURIPOTENT STEM CELLS
20230021826 · 2023-01-26 ·

The present invention relates to a method, which patterns 3D organoids prepared from human pluripotent stem cells and chops the same so as to culture oligodendrocyte progenitor cells, and induces the differentiation thereof so as to obtain a large quantity of finally differentiated oligodendrocytes. Compared to cells differentiated by a conventional differentiation method, oligodendrocytes obtained in a large quantity have the same or superior reproducibility, stability, and functionality and have remarkably shortened differentiation time, and thus are expected to be very useful for cell therapeutic agents or for screening for therapeutic drugs.

HEMATOPOIETIC STEM AND PROGENITOR CELLS DERIVED FROM HEMOGENIC ENDOTHELIAL CELLS BY EPISOMAL PLASMID GENE TRANSFER

Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.

Systems and methods for the production of diphtheria toxin polypeptides

An expression system and process for the production of Diphtheria toxin polypeptides or mutated forms thereof, such as the toxoid CRM197 polypeptide, in genetically-modified E. coli with high yield is described. The system and process is based on the uncoupling of biomass growth from recombinant protein induction, i.e. using an inducer of protein production that cannot be used as a carbon source for growth by the bacteria. The use of specific components and conditions that improve protein yields are also described.

Materials and methods for controlling PHA biosynthesis in PHA-generating species of the genera <i>Ralstonia </i>or <i>Cupriavidus </i>and organisms related thereto

Provided herein are methods for generating cellular biomass in continuous aerobic fermentation systems. The biomass yield, and the concentration of polyhydroxyalkanoate within the biomass, are each directed to advantageous levels by operating the continuous fermentation system under particular nutrient limitation conditions. Also provided are biomass produced using the provided methods, and animal feed compositions including the provided biomass.

METHOD FOR PURIFYING CARDIOMYOCYTES

A method for producing a cell population containing cardiomyocytes, including (1) a step of bringing a histone deacetylase inhibitor into contact with a cell population containing cardiomyocytes and cells other than cardiomyocytes, the cell population being obtained by culturing pluripotent stem cells in a medium for cardiomyocyte differentiation, and (2) a step of culturing the cell population is provided by the present invention.

COMPOSITIONS, SYSTEMS, AND METHODS FOR HIGH LEVEL EXPRESSION OF RECOMBINANT PROTEIN

Improved production of recombinant proteins in E. coli, reliant on tightly controlled autoinduction, triggered by phosphate depletion in stationary phase. The process also provides an optimized autoinduction media, enabling routine batch production at various culture volumes where cells densities routinely reach ˜5-7 g cell dry weight per liter and offer protein titers above 2 g/L. The methodology has been validated with a set of diverse heterologous proteins and is of general use for the facile optimization of routine protein expression from high throughput screens to fed-batch fermentation.

METHOD FOR THE PRODUCTION OF MÜLLER CELLS AND CELL PRODUCT

The present invention relates to a novel process of producing therapeutic GMP grade Müller cells and Miller cells obtainable therefrom, derived from stem cells using products that are free of animal-derived components. The Müller cells are suitable for treatment of eye disease, including glaucoma. There is also provided a cell culture medium.

Cell culture medium

The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.